Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23974875 | 0.81 | GBA1 (0.47) | GBA1CYP19A1HRH4HRH3 | |
| SCHEMBL24725728 | 0.79 | CYP19A1 (0.35) | GBA1CYP19A1NOTUMGGPS1ALOX5 | |
| SCHEMBL24023176 | 0.79 | — | — | |
| SCHEMBL9285404 | 0.79 | — | — | |
| SCHEMBL10065935 | 0.79 | CYP19A1 (0.42) | GBA1CYP19A1NOTUMHRH4GGPS1 | |
| SCHEMBL26699512 | 0.78 | CYP19A1 (0.38) | GBA1CYP19A1HRH4HRH3GGPS1 | |
| Ammonia Solution, Strong SCHEMBL28483640 | 0.77 | CYP19A1 (0.41) | GBA1CYP19A1NOTUM | |
| SCHEMBL20243620 | 0.76 | CYP19A1 (0.41) | GBA1CYP19A1NOTUMHRH4HRH3 | |
| SCHEMBL255017 | 0.76 | GBA1 (0.41) | GBA1CYP19A1NOTUM | |
| SCHEMBL13030153 | 0.75 | ALOX5 (0.59) | CYP19A1HRH4ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351626-B2 | Targeting agent antibody conjugates and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351626-B2 | Targeting agent antibody conjugates and uses thereof | FCGR2A, CD22, FCGR3B | GBA1 1234/4885CYP19A1 4589/4885NOTUM 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.